Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

bluebird bio stock

BLUE
US09609G1004
A1W025

Price

4.08
Today +/-
+0.27
Today %
+7.11 %

bluebird bio stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the bluebird bio stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the bluebird bio stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the bluebird bio stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze bluebird bio's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

bluebird bio Stock Price History

Datebluebird bio Price
2/27/20254.08 undefined
2/26/20253.80 undefined
2/25/20253.86 undefined
2/24/20254.02 undefined
2/23/20254.05 undefined
2/20/20254.08 undefined
2/19/20257.04 undefined
2/18/20257.25 undefined
2/17/20257.12 undefined
2/13/20257.27 undefined
2/12/20257.25 undefined
2/11/20256.39 undefined
2/10/20256.05 undefined
2/9/20256.29 undefined
2/6/20256.29 undefined
2/5/20256.69 undefined
2/4/20256.96 undefined
2/3/20256.96 undefined
2/2/20257.03 undefined

bluebird bio Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into bluebird bio, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by bluebird bio from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects bluebird bio’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of bluebird bio. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into bluebird bio’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing bluebird bio’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on bluebird bio’s growth potential.

bluebird bio Revenue, EBIT and net profit per share

Datebluebird bio Revenuebluebird bio EBITbluebird bio Net Income
2030e691.1 M undefined0 undefined46.94 M undefined
2029e607.92 M undefined24.07 M undefined26.47 M undefined
2028e494.75 M undefined-43.2 M undefined-7.73 M undefined
2027e369.5 M undefined-126.12 M undefined-4.56 M undefined
2026e310.45 M undefined-180.29 M undefined-114.02 M undefined
2025e246.15 M undefined-133.45 M undefined-87.18 M undefined
2024e72.36 M undefined-302.17 M undefined-221.38 M undefined
202329.5 M undefined-337.19 M undefined-211.91 M undefined
20223.6 M undefined-384.15 M undefined-266.58 M undefined
20213.66 M undefined-565.11 M undefined-819.38 M undefined
20200 undefined-559.26 M undefined-618.7 M undefined
20190 undefined-562.96 M undefined-789.61 M undefined
201854.58 M undefined-572.02 M undefined-555.63 M undefined
201735.43 M undefined-332.17 M undefined-335.64 M undefined
20166.16 M undefined-267.83 M undefined-263.51 M undefined
201514.08 M undefined-169.04 M undefined-166.78 M undefined
201425.42 M undefined-60.63 M undefined-48.71 M undefined
201320.18 M undefined-24.95 M undefined-25.32 M undefined
2012340,000 undefined-23.72 M undefined-3.61 M undefined
2011880,000 undefined-15.14 M undefined-20.59 M undefined

bluebird bio Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
002025146355400332972246310369494607691
---25.00-44.00-57.14483.3354.29----866.67148.28241.6726.0219.0333.8822.8713.84
---20.00-16.00-28.57-66.6794.2998.15---1,166.67-200.00-13.79-5.56-1.63-1.29-1.08-0.81-0.66-0.58
000000335300-35-6-40000000
-20-3-25-48-166-263-335-555-789-618-819-266-211-221-87-114-4-72646
--85.00733.3392.00245.8358.4327.3865.6742.16-21.6732.52-67.52-20.684.74-60.6331.03-96.4975.00-471.4376.92
0.120.2612.5626.5534.6737.2843.5452.0355.1962.1868.9178.595.490000000
--------------------
Details

Keystats

ⓘ

Revenue and Growth

The bluebird bio Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the bluebird bio is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
2011201220132014201520162017201820192020202120222023
                         
0.030.070.210.470.520.71.291.391.111.150.30.180.22
00000000400400000
0000000000000
00000000000022.92
0.90.85.76.4619.829.633.745.363.93719.237.01
0.030.070.210.480.520.721.321.421.151.220.340.20.28
0.71.310.915.782.6157199.6246.6337.1346.9101.2291.4267.05
00018.4347.8180.5324.2506.1131.5122.997.11.40
0000000000000
00028.224.520.716.913.214.31004.910.44
00013.113.113.113.113.113.113.15.65.65.65
0.20.31.51.210.422.723.944.879.272.853.352.154.34
0.91.612.476.6478.4394577.7823.8575.2565.7257.2355.4337.48
0.030.070.220.5611.121.92.241.731.780.590.550.62
                         
82.4122.20.20.30.40.40.50.50.60.70.70.81.91
0.010.020.250.641.171.452.543.393.574.264.14.194.45
-63.4-73.4-98.7-147.4-314.2-577.7-913.8-1,498.8-2,281.9-2,900.5-3,719.9-3,986.5-4,260.33
000-0.1-2.3-1.1-4.2-3.6-1.9-5.5-2.9-4.1-1.8
0000000000000
0.030.060.150.490.850.871.621.891.281.360.370.20.19
1.82.24.436.313.712.917.84321.625.925.118.5
0.72.14.212.723.149.555.296.7136.4149.8123.7100.988.79
0.40.426.427.310.911.326.530.544.232.23.42.38.12
0000000000000
0000001.11.4000084.71
2.94.7354340.374.595.7146.4223.6203.6153128.3200.11
000061.9120.1154.7153.3000037.73
000.71.9000000000
1.30.637.220.649.65426.858218.9222.666.5230.3186.78
1.30.637.922.5111.5174.1181.5211.3218.9222.666.5230.3224.51
4.25.372.965.5151.8248.6277.2357.7442.5426.2219.5358.6424.62
0.030.070.220.5611.121.92.241.731.780.590.550.62
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of bluebird bio provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand bluebird bio's financial health and stability.

Assets

bluebird bio's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that bluebird bio must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of bluebird bio after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into bluebird bio's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201120122013201420152016201720182019202020212022
-15-23-25-48-166-263-335-555-789-618-819-266
00047913171719195
000000000000
2160-141518-121946-2817-39
1113108685107216322314274-17
00000011150000
000000000000
-12-2143-59-98-189-280-413-564-470-635-352
00-8-8-7-28-62-55-76-28-23-13
-32-9-157-57167-316-679507-84562250
-33-1-148-56495-254-623584-55585263
000000000000
0000000-10000
0.030.060.110.360.490.241.040.740.020.550.080.05
0.030.060.110.360.490.241.080.740.020.55-0.090.05
00000036300-1740
000000000000
1641139141-183118478-355-35-7-167-48
-12.62-21.9134.78-68.4-105.49-217.68-342.79-469.17-640.63-499.34-658.64-366.16
000000000000

bluebird bio stock margins

The bluebird bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of bluebird bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for bluebird bio.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the bluebird bio's sales revenue. A higher gross margin percentage indicates that the bluebird bio retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the bluebird bio's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the bluebird bio's total revenue generated. When comparing the revenue margin year over year, investors can gauge the bluebird bio's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the bluebird bio. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the bluebird bio's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

bluebird bio Margin History

bluebird bio Gross marginbluebird bio Profit marginbluebird bio EBIT marginbluebird bio Profit margin
2030e-13.66 %0 %6.79 %
2029e-13.66 %3.96 %4.35 %
2028e-13.66 %-8.73 %-1.56 %
2027e-13.66 %-34.13 %-1.23 %
2026e-13.66 %-58.07 %-36.73 %
2025e-13.66 %-54.21 %-35.42 %
2024e-13.66 %-417.62 %-305.96 %
2023-13.66 %-1,143.14 %-718.42 %
2022-180 %-10,670.83 %-7,405 %
2021-961.75 %-15,440.16 %-22,387.43 %
2020-13.66 %0 %0 %
2019-13.66 %0 %0 %
201898.37 %-1,048.04 %-1,018.01 %
201795.68 %-937.54 %-947.33 %
2016-13.66 %-4,347.89 %-4,277.76 %
2015-13.66 %-1,200.57 %-1,184.52 %
2014-13.66 %-238.51 %-191.62 %
2013-13.66 %-123.64 %-125.47 %
2012-13.66 %-6,976.47 %-1,061.76 %
2011-13.66 %-1,720.45 %-2,339.77 %

bluebird bio Stock Sales Revenue, EBIT, Earnings per Share

The bluebird bio earnings per share therefore indicates how much revenue bluebird bio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue bluebird bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates bluebird bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of bluebird bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating bluebird bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

bluebird bio Revenue, EBIT and net profit per share

Datebluebird bio Sales per Sharebluebird bio EBIT per sharebluebird bio Earnings per Share
2030e71.1 undefined0 undefined4.83 undefined
2029e62.54 undefined0 undefined2.72 undefined
2028e50.9 undefined0 undefined-0.8 undefined
2027e38.01 undefined0 undefined-0.47 undefined
2026e31.94 undefined0 undefined-11.73 undefined
2025e25.32 undefined0 undefined-8.97 undefined
2024e7.44 undefined0 undefined-22.78 undefined
20235.37 undefined-61.4 undefined-38.59 undefined
20220.05 undefined-4.89 undefined-3.39 undefined
20210.05 undefined-8.2 undefined-11.89 undefined
20200 undefined-8.99 undefined-9.95 undefined
20190 undefined-10.2 undefined-14.31 undefined
20181.05 undefined-10.99 undefined-10.68 undefined
20170.81 undefined-7.63 undefined-7.71 undefined
20160.17 undefined-7.18 undefined-7.07 undefined
20150.41 undefined-4.88 undefined-4.81 undefined
20140.96 undefined-2.28 undefined-1.83 undefined
20131.61 undefined-1.99 undefined-2.02 undefined
20121.31 undefined-91.23 undefined-13.88 undefined
20117.33 undefined-126.17 undefined-171.58 undefined

bluebird bio business model

Bluebird bio Inc is a biotechnology company that was founded in 1992 in Cambridge, Massachusetts. The company specializes in the development of gene therapies and stem cell therapies for the treatment of cancer and genetic diseases. The goal of bluebird bio Inc is to develop innovative and effective therapies that can improve the lives of people with serious illnesses. bluebird bio is one of the most popular companies on Eulerpool.com.

bluebird bio SWOT Analysis

Strengths

  • Strong focus on gene therapy development and innovation, positioning bluebird bio Inc as a pioneer in the field.
  • Extensive intellectual property portfolio and know-how in gene editing technologies, providing a competitive advantage.
  • Robust pipeline with promising gene therapy candidates targeting various diseases and rare genetic disorders.
  • Strategic partnerships with leading pharmaceutical companies, facilitating research collaborations and potential commercialization opportunities.
  • High-quality manufacturing capabilities and expertise to support clinical trials and commercial production of gene therapies.

Weaknesses

  • Dependence on a few key pipeline candidates, making the company vulnerable to potential failures or setbacks.
  • Regulatory and clinical uncertainties related to gene therapies, requiring substantial investment and time for product development.
  • Relatively small-scale operations and limited market presence compared to larger pharmaceutical companies in the industry.
  • Heavy reliance on external funding and partnerships for research and development activities, resulting in potential financial risks.

Opportunities

  • Growing acceptance and demand for gene therapies, driven by advancements in biotechnology and increasing prevalence of genetic diseases.
  • Potential expansion into global markets, leveraging partnerships and obtaining regulatory approvals in key regions.
  • Development of novel gene editing platforms and technologies, presenting opportunities to enhance therapeutic efficacy and expand treatment applications.
  • Collaboration opportunities with academic institutions and research organizations to further advance gene therapy research and development.

Threats

  • Intense competition from established pharmaceutical companies and emerging biotech firms entering the gene therapy space.
  • Regulatory and reimbursement challenges for gene therapies, including pricing uncertainties and market access barriers.
  • Potential safety and efficacy concerns associated with gene editing technologies, leading to regulatory scrutiny and public skepticism.
  • Reliance on successful clinical trial results to obtain regulatory approvals and market acceptance, posing inherent risks.

bluebird bio Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

bluebird bio Revenue by Segment

Segmente202220192018
Collaboration arrangement--38.44 M USD
Collaboration revenue-36.47 M USD-
License and royalty revenue-8.21 M USD-
Product revenue2.74 M USD--
License and royalty--2.23 M USD
Other revenue858,000 USD--
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

bluebird bio Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

bluebird bio historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

bluebird bio shares outstanding

The number of shares was bluebird bio in 2024 — This indicates how many shares 5.491 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue bluebird bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates bluebird bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of bluebird bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating bluebird bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

bluebird bio stock splits

In bluebird bio's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for bluebird bio.

bluebird bio latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-7.43 -6.2  (16.57 %)2024 Q3
6/30/2024-8.5 -8.4  (1.18 %)2024 Q2
3/31/2024-8.99 -7.2  (19.91 %)2024 Q1
9/30/2023-0.69 -0.66  (4.11 %)2023 Q3
6/30/2023-0.73 -0.67  (8.21 %)2023 Q2
3/31/2023-0.38 0.21  (155.64 %)2023 Q1
12/31/2022-0.44 -0.81  (-82.15 %)2022 Q4
9/30/2022-1.14 -0.94  (17.49 %)2022 Q3
6/30/2022-1.26 -1.27  (-0.71 %)2022 Q2
3/31/2022-1.42 -1.66  (-16.85 %)2022 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the bluebird bio stock

Eulerpool World ESG Rating (EESG©)

44/ 100

🌱 Environment

41

👫 Social

39

🏛️ Governance

51

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

bluebird bio shareholders

%
Name
Stocks
Change
Date
6.69372 % BlackRock Institutional Trust Company, N.A.650,630-61,30412/31/2024
5.40549 % The Vanguard Group, Inc.525,4141,71412/31/2024
2.40241 % Geode Capital Management, L.L.C.233,514-63812/31/2024
2.03622 % State Street Global Advisors (US)197,9215,82512/31/2024
1.69753 % ACATIS Investment Kapitalverwaltungsgesellschaft GmbH165,000011/30/2024
1.05712 % UBS Financial Services, Inc.102,75297,79712/31/2024
0.84058 % National Bank of Canada81,70481,70012/31/2024
0.83905 % Northern Trust Investments, Inc.81,55611,04512/31/2024
0.83904 % Avidity Partners Management LP81,555-212/31/2024
0.81185 % Lion Point Capital, L.P.78,912-112/31/2024
1
2
3
4
5
...
10

bluebird bio Executives and Management Board

Mr. Andrew Obenshain

(49)
bluebird bio President, Chief Executive Officer, Director (since 2021)
Compensation 1.81 M

Dr. Richard Colvin

(57)
bluebird bio Chief Medical Officer
Compensation 1.36 M

Mr. Thomas Klima

(51)
bluebird bio Chief Commercial and Operating Officer
Compensation 1.25 M

Mr. Mark Vachon

bluebird bio Independent Chairman of the Board
Compensation 142,230

Dr. Charlotte Jones-Burton

bluebird bio Independent Director
Compensation 108,871
1
2
3

Most common questions regarding bluebird bio

What values and corporate philosophy does bluebird bio represent?

Bluebird bio Inc represents values of innovation, integrity, and patient-centricity. The company is driven by a corporate philosophy that centers around transforming the lives of patients with severe diseases through the development of potentially curative gene therapies. With a focus on revolutionizing the approach to treating genetic diseases, bluebird bio Inc is committed to harnessing the power of gene therapy and gene editing technologies to provide long-term and durable solutions for patients in need. By prioritizing scientific excellence and collaboration, bluebird bio Inc strives to advance the field of gene therapy and improve outcomes for patients worldwide.

In which countries and regions is bluebird bio primarily present?

Bluebird bio Inc is primarily present in the United States, with its headquarters located in Cambridge, Massachusetts. As a leading biotechnology company, bluebird bio Inc focuses on developing gene therapies for severe genetic diseases and cancer. It operates across various states in the US and has a significant presence in the biotech hubs of California and North Carolina. While its primary presence is in the US, bluebird bio Inc also has a global presence through collaborations and partnerships with international research institutions and pharmaceutical companies.

What significant milestones has the company bluebird bio achieved?

Some significant milestones achieved by Bluebird Bio Inc include the approval and commercialization of their groundbreaking gene therapy, ZYNTeglo, for the treatment of transfusion-dependent β-thalassemia. The company also received regulatory approval for their gene therapy product, Skysona, for the treatment of cerebral adrenoleukodystrophy. Bluebird Bio has successfully advanced its portfolio of gene and cell therapies for various genetic diseases, pushing the boundaries of treatment options available for patients. Additionally, the company collaborated with Bristol Myers Squibb to develop and commercialize novel cancer therapies, aimed at further advancing personalized medicine.

What is the history and background of the company bluebird bio?

Bluebird bio Inc is a renowned biotechnology company specializing in gene therapy. Founded in 1992, it has its headquarters in Cambridge, Massachusetts. The company is dedicated to developing potentially transformative gene therapies for severe genetic and rare diseases. Bluebird bio Inc's cutting-edge research and innovation aim to improve patients' lives by addressing the underlying causes of their diseases. With a strong focus on cell and gene therapies, they leverage their expertise to create groundbreaking treatments. Bluebird bio Inc has established collaborations with leading healthcare organizations, further advancing their pioneering work in the field of gene therapy.

Who are the main competitors of bluebird bio in the market?

The main competitors of bluebird bio Inc in the market include CRISPR Therapeutics, Editas Medicine, Sangamo Therapeutics, and Intellia Therapeutics.

In which industries is bluebird bio primarily active?

Bluebird bio Inc is primarily active in the biotechnology industry.

What is the business model of bluebird bio?

The business model of bluebird bio Inc is focused on developing and commercializing transformative gene therapies for severe genetic diseases and cancer. Through its innovative gene editing and delivery technologies, bluebird bio aims to provide potentially curative treatments for patients with limited or no treatment options. The company's approach involves genetically modifying a patient's own cells to produce functional proteins, correct genetic mutations, or enhance the immune system to target and eliminate cancer cells. With a goal of improving patients' lives, bluebird bio works towards advancing gene therapy research and expanding its portfolio to address various genetic diseases and conditions.

What is the P/E ratio of bluebird bio 2025?

The bluebird bio P/E ratio is -0.26.

What is the P/S ratio of bluebird bio 2025?

The bluebird bio P/S ratio is 0.09.

What is the Quality Investing of bluebird bio?

The Quality Investing for bluebird bio is 4/10.

What is the revenue of bluebird bio 2025?

The expected bluebird bio revenue is 246.15 M USD.

How high is the profit of bluebird bio 2025?

The expected bluebird bio profit is -87.18 M USD.

What is the business model of bluebird bio

The company bluebird bio Inc. is a biotechnology company based in Massachusetts, USA. It was founded in 1992 and specializes in the research, development, and commercialization of therapies for serious diseases. The company focuses on gene therapies and stem cell therapies for diseases that traditional medications cannot sufficiently treat. The company currently has three major divisions: Oncology, Rare Diseases, and Cancer Immunotherapy. In the oncology division, bluebird bio is researching and developing gene therapies for the treatment of leukemia and myeloma. The company has already received approvals for its therapy for beta-thalassemia and is actively developing gene therapies for other diseases such as sickle cell anemia. In the rare diseases field, the company is also developing gene therapies for inherited diseases. One of its key therapies in this area is the LentiGlobin beta-thalassemia therapy. The cancer immunotherapy division is dedicated to developing therapies that utilize the immune system to fight cancer. The company offers a range of products, including gene therapies, stem cell therapies, and cell therapies. One of these is the Lenti-D therapy, used for the treatment of orphan diseases like childhood leukodystrophy (MLD). Another important therapy is the LentiGlobin beta-thalassemia therapy for the treatment of beta-thalassemia. The company has also developed a cell therapy called BB2121, used for multiple myeloma. The business model of bluebird bio is based on developing innovative therapies to cure serious diseases that traditional medications cannot reach. The company works closely with regulatory authorities in the US and Europe to effectively and quickly market its therapies once they are approved. In the past, the company has formed partnerships with other biotechnology and pharmaceutical companies to advance its research and development. There are numerous ongoing clinical research projects that the company is currently conducting to bring new therapies to the market. Overall, bluebird bio has strong venture capital and investor support. In December 2016, the company announced a partnership with Celgene, one of the largest biotech companies in the world, to jointly develop therapies for treating cancer. In conclusion, bluebird bio is a biotechnology company that specializes in researching and developing gene therapies, stem cell therapies, and cell therapies to treat serious diseases that traditional medications cannot reach. It offers a range of products and actively works on developing therapies that utilize the immune system to effectively fight cancer. The company collaborates closely with regulatory authorities and other companies to conduct its research and development and bring new therapies to the market.

What is the bluebird bio dividend?

bluebird bio pays a dividend of 0 USD distributed over payouts per year.

How often does bluebird bio pay dividends?

The dividend cannot currently be calculated for bluebird bio or the company does not pay out a dividend.

What is the bluebird bio ISIN?

The ISIN of bluebird bio is US09609G1004.

What is the bluebird bio WKN?

The WKN of bluebird bio is A1W025.

What is the bluebird bio ticker?

The ticker of bluebird bio is BLUE.

How much dividend does bluebird bio pay?

Over the past 12 months, bluebird bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, bluebird bio is expected to pay a dividend of 0 USD.

What is the dividend yield of bluebird bio?

The current dividend yield of bluebird bio is .

When does bluebird bio pay dividends?

bluebird bio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of bluebird bio?

bluebird bio paid dividends every year for the past 0 years.

What is the dividend of bluebird bio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is bluebird bio located?

bluebird bio is assigned to the 'Health' sector.

Wann musste ich die Aktien von bluebird bio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of bluebird bio from 3/3/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/3/2025.

When did bluebird bio pay the last dividend?

The last dividend was paid out on 3/3/2025.

What was the dividend of bluebird bio in the year 2024?

In the year 2024, bluebird bio distributed 0 USD as dividends.

In which currency does bluebird bio pay out the dividend?

The dividends of bluebird bio are distributed in USD.

All fundamentals about bluebird bio

Our stock analysis for bluebird bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of bluebird bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.